DC Field | Value | Language |
---|---|---|
dc.contributor.author | Deog Yeon Jo | - |
dc.contributor.author | Jee Young Choi | - |
dc.contributor.author | Hwan Jung Yun | - |
dc.contributor.author | Eui Gun Chun | - |
dc.contributor.author | Jun Young Kil | - |
dc.contributor.author | Samyong Kim | - |
dc.contributor.author | Yun Soo Bae | - |
dc.contributor.author | In Seong Choe | - |
dc.date.accessioned | 2017-04-19T08:55:16Z | - |
dc.date.available | 2017-04-19T08:55:16Z | - |
dc.date.issued | 1993 | - |
dc.identifier.issn | I000-0079 | - |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/4354 | - |
dc.publisher | Korea Soc-Assoc-Inst | - |
dc.title | Interleukin-1 수용체 길항제에 의한 만성골수백혈병 집락형성 및 K562세포 증식 억제 | - |
dc.title.alternative | Suppression of chronic myelogenous leukemia colony growth and K562 cell proliferation by Interleukin-1 receptor antagonist | - |
dc.type | Article | - |
dc.citation.title | Korean Journal of Hematology | - |
dc.citation.number | 2 | - |
dc.citation.endPage | 283 | - |
dc.citation.startPage | 277 | - |
dc.citation.volume | 28 | - |
dc.contributor.affiliatedAuthor | In Seong Choe | - |
dc.contributor.alternativeName | 조덕연 | - |
dc.contributor.alternativeName | 최지영 | - |
dc.contributor.alternativeName | 윤환중 | - |
dc.contributor.alternativeName | 전의건 | - |
dc.contributor.alternativeName | 길준영 | - |
dc.contributor.alternativeName | 김삼용 | - |
dc.contributor.alternativeName | 배윤수 | - |
dc.contributor.alternativeName | 최인성 | - |
dc.identifier.bibliographicCitation | Korean Journal of Hematology, vol. 28, no. 2, pp. 277-283 | - |
dc.subject.keyword | Chronic Myelogenous Leukemia | - |
dc.subject.keyword | IL-1 Receptor Antagonist | - |
dc.subject.keyword | Interferon | - |
dc.subject.local | Chronic Myelogenous Leukemia | - |
dc.subject.local | IL-1 Receptor Antagonist | - |
dc.subject.local | Interferon | - |
dc.subject.local | interferon | - |
dc.description.journalClass | N | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.